Identifying new targets for monoclonal antibodies in immunotherapy
Official title: Nuovi Bersagli Per lo Sviluppo di Anticorpi Monoclonali Per Immunoterapia - (Novel Targets for the Development of Monoclonal Antibodies for Immunotherapy)
Run by Checkmab S.r.l. · NCT06842407 · Data updated 2026-11-12
This study is testing new targets for cancer treatment by looking at immune cells in healthy blood donors to see if certain antibodies can help improve immunotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 600 (estimated) |
| Sponsor | Checkmab S.r.l. Industry-sponsored |
| Locations | 1 site (Milan) |
| Status | Recruiting |
| Started | April 1, 2023 |
| Main results expected | June 30, 2026 |
| Study ends | June 30, 2026 |
| Registry record updated | February 24, 2025 |
| Trial ID | NCT06842407 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are healthy adults aged 18 years or older who are eligible to donate blood.
✕Probably not a fit
Patients who are under 18 years old or have infectious diseases such as HIV, HCV, or HBV will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project aims to preclinically validate new molecular targets associated with intratumoral T regulatory cells. It will also involve selecting monoclonal antibodies that have therapeutic potential specific to these targets. The study focuses on healthy blood donors who meet specific eligibility criteria, allowing for the exploration of immune responses relevant to cancer treatment. By identifying these targets, the research could pave the way for innovative immunotherapeutic strategies.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective immunotherapies for cancer patients.
How similar studies have gone: While this approach is innovative, similar studies targeting T regulatory cells have shown promise in the past, indicating potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * blood donors * age of 18 years or more * able to sign informed consent Exclusion Criteria: * age below 18 years * Positive for HIV, HCV, HBV * not suitable for blood donation * not able to understand or sign informed consent
Where it's running
-
S.C. Medicina Trasfusionale - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy Recruiting
Study contacts
- Study coordinator: Renata M Grifantini, PhD
- Email: renata.grifantini@checkmab.eu
- Phone: 0039 00660220
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Impact of seaweed food additive carrageenan on gut health
This study tests whether a seaweed food additive called carrageenan can improve gut health in healthy people by changing their gut bacteria and making them feel better.
-
Collecting blood samples from cancer patients and healthy donors to study immune cells
This study is trying to see if it's possible to collect and grow certain immune cells from both cancer patients and healthy people to understand how well these cells can fight cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.